Recently published data from a number of sources appear to suggest that the oral hypoglycaemic agent metformin may prevent abdominal aortic aneurysm (AAA) development, attenuate growth, and perhaps even prevent rupture. Previous studies have hinted that hypoglycaemic agents might reduce AAA expansion.1 The latest data, specific to metformin are compelling. Metformin is a biologically plausible drug since it has a wide range of effects on inflammation and metabolism. Potentially exciting observations remain preliminary and should be interpreted with caution.
|Number of pages||2|
|Journal||European Journal of Vascular and Endovascular Surgery|
|Early online date||5 Oct 2017|
|Publication status||Published - Dec 2017|
- Centre for Surgical Research